Release Details

Paris, October 15, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing therapeutic anti-viral drugs and vaccines, today announced the participation of its CEO, Prof. Dr. Hartmut Ehrlich, at the BIO Europe 2015 conference, to be held in Munich on November 2^nd to 4^th, and at the Deutsches Eigenkapitalforum to be held in Frankfurt on November 23^rd and 24^th.  Prof. Ehrlich will make presentations on ABIVAX’s current development program and strategy at both .